Stockscreener 앱 받기
5.16
0.58%
-0.03
시간 외 거래:
5.14
-0.02
-0.39%
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Expands Team: 7 New Hires Receive Major Equity Package Worth $1.1M - Stock Titan
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Why Verve Therapeutics Zoomed 40% Higher This Week - MSN
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus
Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - MSN
Verve impresses investors with second shot at PCSK9 - BioCentury
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade - marketscreener.com
Why Verve Therapeutics Is Skyrocketing Today - The Globe and Mail
Guggenheim raises Verve Therapeutics stock target to $24 By Investing.com - Investing.com Canada
Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Shakes Market with New Genomic Breakthrough - timothysykes.com
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral - marketscreener.com
0.39%
3.66%
자본화:
|
볼륨(24시간):